Yin Y - Search Results

1

Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials.

Bao S, Yue Y, Hua Y, Zeng T, Yang Y, Yang F, Yan X, Sun C, Yang M, Fu Z, Huang X, Li J, Wu H, Li W, Zhao Y, Yin Y. Bao S, et al. Among authors: yin y. Ann Transl Med. 2021 Aug;9(15):1229. doi: 10.21037/atm-21-1883. Ann Transl Med. 2021. PMID: 34532366 Free PMC article.

2

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.

Yin YM, Geng YT, Shao YF, Hu XL, Li W, Shu YQ, Wang ZX. Yin YM, et al. J Exp Clin Cancer Res. 2010 Sep 15;29(1):126. doi: 10.1186/1756-9966-29-126. J Exp Clin Cancer Res. 2010. PMID: 20843324 Free PMC article.

3

Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.

Chen X, Li W, Hu X, Geng Y, Wang R, Yin Y, Shu Y. Chen X, et al. Among authors: yin y. Biomed Pharmacother. 2011 Dec;65(8):542-6. doi: 10.1016/j.biopha.2011.04.017. Epub 2011 Jun 12. Biomed Pharmacother. 2011. PMID: 21840160 Clinical Trial.

4

Regulation of CD44 expression by tumor necrosis factor-α and its potential role in breast cancer cell migration.

Li J, Zha XM, Wang R, Li XD, Xu B, Xu YJ, Yin YM. Li J, et al. Biomed Pharmacother. 2012 Mar;66(2):144-50. doi: 10.1016/j.biopha.2011.11.021. Epub 2012 Feb 17. Biomed Pharmacother. 2012. PMID: 22386367

5

Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.

Chen X, Zha X, Chen W, Zhu T, Qiu J, Røe OD, Li J, Wang Z, Yin Y. Chen X, et al. Among authors: yin y. Biomed Pharmacother. 2013 Feb;67(1):22-30. doi: 10.1016/j.biopha.2012.10.001. Epub 2012 Nov 15. Biomed Pharmacother. 2013. PMID: 23199901

6

Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.

Yu S, Zhang B, Xiang C, Shu Y, Wu H, Huang X, Yu Q, Yin Y, Guo R. Yu S, et al. Among authors: yin y. Clin Lung Cancer. 2015 Mar;16(2):121-7. doi: 10.1016/j.cllc.2014.09.007. Epub 2014 Sep 30. Clin Lung Cancer. 2015. PMID: 25450874 Clinical Trial.

7

LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer.

Lv M, Xu P, Wu Y, Huang L, Li W, Lv S, Wu X, Zeng X, Shen R, Jia X, Yin Y, Gu Y, Yuan H, Xie H, Fu Z. Lv M, et al. Among authors: yin y. Oncotarget. 2016 Mar 15;7(11):13047-59. doi: 10.18632/oncotarget.7509. Oncotarget. 2016. PMID: 26910840 Free PMC article.

8

Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo.

Lu X, Yan C, Huang Y, Shi D, Fu Z, Qiu J, Yin Y. Lu X, et al. Among authors: yin y. Oncotarget. 2016 Jun 14;7(24):37177-37191. doi: 10.18632/oncotarget.9287. Oncotarget. 2016. PMID: 27184007 Free PMC article.

9

Suppressing role of miR-520a-3p in breast cancer through CCND1 and CD44.

Li J, Wei J, Mei Z, Yin Y, Li Y, Lu M, Jin S. Li J, et al. Among authors: yin y. Am J Transl Res. 2017 Jan 15;9(1):146-154. eCollection 2017. Am J Transl Res. 2017. PMID: 28123641 Free PMC article.

10

Roles of cancer/testis antigens (CTAs) in breast cancer.

Li Y, Li J, Wang Y, Zhang Y, Chu J, Sun C, Fu Z, Huang Y, Zhang H, Yuan H, Yin Y. Li Y, et al. Among authors: yin y. Cancer Lett. 2017 Jul 28;399:64-73. doi: 10.1016/j.canlet.2017.02.031. Epub 2017 Mar 6. Cancer Lett. 2017. PMID: 28274891

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14,154 results

Search Page

Filters